Results 301 to 310 of about 3,082,206 (396)

A case of EGFR-positive lung adenocarcinoma that once transformed into small cell carcinoma but worsened into adenocarcinoma again. [PDF]

Respir Med Case Rep
Tanaka S, Yokota K, Yoshimura N, Tobita S, Yaga M, Ueno K.   +5 more
europepmc   +1 more source

LMO7 Suppresses Tumor‐Associated Macrophage Phagocytosis of Tumor Cells Through Degradation of LRP1

Advanced Science, EarlyView.
LMO7 in tumor‐associated macrophages suppresses phagocytosis of tumor cells and limits cytotoxic T lymphocytes infiltration, fostering tumor progression. Mechanistically, LMO7 mediates the ubiquitination and degradation of the phagocytic receptor LRP1, impairing its ability to engulf tumor cells and driving macrophages toward an antitumor phenotype ...
Mengkai Li, Tao Wang, Yuwen Zhong, Zhiming Wang, Wei Li, Zejian Wang, Xinyi Yang, Yu Qiao, Jianfeng Xiang, Wei Gu, Zishu Wang, Lei Sun, Feng Qian   +12 more
wiley   +1 more source

Primary pleural small cell carcinoma with massive pleural effusion: A rare case report. [PDF]

Int J Surg Case Rep
Rabha P, Wisely JP, Jain A, Raina V, Ahlawat S, Das S.   +5 more
europepmc   +1 more source

B4GALNT4‐Mediated Glycosylation of PDK1 Activates the PI3K‐AKT Signaling Pathway to Promote Prostate Cancer Progression

Advanced Science, EarlyView.
This study identifies B4GALNT4 as a key driver of prostate cancer (PCa). It shows that B4GALNT4 glycosylates PDK1 protein at the N531 site, which stabilizes the PDK1 and constitutively activates the PI3K‐AKT pathway. This mechanism promotes tumor cell proliferation, migration, and invasion. The findings establish the B4GALNT4‐PDK1 glycosylation axis as
Shaoqin Jiang, Mengqiang Li, Qingfu Su, Ruiling Dou, Shaoshan Lin, Jili Zhang, Xiaochen Sun, Haolan Yu, Wei Bao, Min Qu, Yan Wang, Chenghua Yang, Xu Gao   +12 more
wiley   +1 more source

Clinicopathological characteristics of transcription factor-defined subtypes in bladder small cell carcinoma. [PDF]

BMC Cancer
Kitahama K, Shigematsu Y, Sugawara E, Amori M, Amori G, Saito R, Ohmoto A, Yonese J, Takeuchi K, Inamura K.   +9 more
europepmc   +1 more source

CDK4/6 Inhibition Induces CD8+ T Cell Antitumor Immunity via MIF‐Induced Functional Orchestration of Tumor‐Associated Macrophages

Advanced Science, EarlyView.
CDK4/6 inhibition promotes CD8+ T cell expansion through tumor‐macrophage crosstalk by activating HIF‐1α and enhancing MIF‐CD44/CD74 signaling. This reprograms TAMs to boost MHC‐I antigen presentation, and CDK4/6 inhibitor‐trained M1 TAM supernatant therapy synergizes with low‐dose PD‐1 blockade to restore antitumor immunity.
Lin He, Yuzhong Peng, Lat‐lun Leong, Jingbo Zhou, Dongyang Tang, Weilu Wang, Xiaoran Wu, Josh haipeng Lei, Yongqin Ye, Yangyang Feng, Yunfeng Qiao, Xiangpeng Chu, Di Mu, Qi Zhao, Tzuming Liu, Yan Chen, Paul Kwonghang Tam, Chu‐Xia Deng   +17 more
wiley   +1 more source

Double Trouble: Synchronous Small Cell Carcinoma and Adenocarcinoma of the Pancreas - Case Report. [PDF]

Case Rep Oncol
Thomas RJ, Zeineddine M, Chatterjee A, Cruise M, Krishnamurthi S, Chahal P.   +5 more
europepmc   +1 more source

Multiple Somatic Mutations of SMARCA4 in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: A Case Report [PDF]

Yoko Aoyagi, Kentaro Kai, Haruto Nishida, Saki Aso, Eiji Kobayashi   +4 more
openalex   +1 more source

Pathogenic Role of FGFR3 Autoantibodies in Small Fiber Neuropathy

Advanced Science, EarlyView.
Autoantibodies against fibroblast growth factor receptor 3 (FGFR3) are identified as pathogenic drivers of pain in small fiber neuropathy. By binding to sensory neurons in dorsal root ganglia, FGFR3 autoantibodies activate MAPK signaling and induce hyperexcitability and mechanical hypersensitivity, establishing FGFR3 autoantibodies as a therapeutic ...
Lyuba Y. Salih, Nicolas L.A. Dumaire, Clémence Gieré, Erin Vest, Haya Alkhateeb, Christian P. Moritz, Yannick Tholance, Jean‐Philippe Camdessanché, Jean‐Christophe Antoine, Jérôme Honnorat, Jafar Kafaie, Liberty François‐Moutal, Aubin Moutal   +12 more
wiley   +1 more source

Salvage sequential integrated boost radiotherapy followed by sintilimab-bevacizumab in cervical small-cell carcinoma with >10 brain metastases: A 3-year survivor case report. [PDF]

Front Immunol
Xu Y, Gong X, He H, Deng X, Zhang Z, Wen Q, Li D.   +6 more
europepmc   +1 more source